{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:06:10Z","timestamp":1777853170616,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with drug-resistant HIV often require complex antiretroviral regimens. However, combining fixed-dose combination tablets such as tenofovir\u2013disoproxil\u2013fumarate, emtricitabine, and cobicistat-boosted elvitegravir (TDF\/FTC\/EVG\/cobi) with darunavir (DRV) can provide a simple, once-daily (QD), 2-tablet regimen for patients with drug-resistant HIV. Primary objective was to determine the percentage of patients with HIV-1 RNA &lt;40 copies\/mL at 48 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective chart review of patients initiated on TDF\/FTC\/EVG\/cobi plus DRV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 21 included patients, prior resistance showed a median of 2 nucleoside reverse transcriptase inhibitor mutations, 1 nonnucleoside reverse transcriptase mutation, and 1 protease inhibitor mutation. At week 48, 14 (67%) patients achieved HIV-1 RNA &lt;40 copies\/mL, 1 patient experienced viral rebound, and 6 (29%) had missing data or discontinued therapy. No patient discontinued for adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>According to this observational study, QD TDF\/FTC\/EVG\/cobi plus DRV is considered safe, well tolerated, and generally effective in suppressing HIV drug-resistant virus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2325957417752260","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T04:51:23Z","timestamp":1517460683000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination Therapy with Tenofovir Disoproxil Fumarate\/Emtricitabine\/Elvitegravir\/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review"],"prefix":"10.1177","volume":"17","author":[{"given":"Mark J.","family":"Naccarato","sequence":"first","affiliation":[{"name":"Department of Pharmacy, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, St Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah M.","family":"Yoong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, St Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignatius W.","family":"Fong","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, St Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Gough","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian A.","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Keenan Research Centre for Biomedical Science, St Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell H. S.","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre for Research on Inner City Health, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"bibr1-2325957417752260","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1662"},{"key":"bibr2-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1086\/630210"},{"key":"bibr3-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1086\/313849"},{"key":"bibr4-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1310\/hct0902-103"},{"key":"bibr5-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077691"},{"key":"bibr6-2325957417752260","first-page":"115","volume":"4","author":"Airoldi M","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"bibr7-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033"},{"key":"bibr8-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a209"},{"key":"bibr9-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2009.0259"},{"key":"bibr10-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01046.x"},{"key":"bibr11-2325957417752260","unstructured":"Gilead Sciences Canada Inc. Stribild (elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate) Product Monograph. Mississauga, Ontario: Gilead Sciences Canada Inc; 2014"},{"key":"bibr12-2325957417752260","unstructured":"FDA. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm355128.pdf. 2015. Accessed January 3, 2018."},{"issue":"3","key":"bibr13-2325957417752260","first-page":"642","volume":"22","author":"Wensing AM","year":"2014","journal-title":"Top Antivir Med"},{"key":"bibr14-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1086\/505356"},{"key":"bibr15-2325957417752260","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/division-of-aids-(daids)-table-for-grading-the-severity-of-adult-and-pediatric-adverse-events-corrected-v-2-1.pdf. Accessed January 3, 2018."},{"key":"bibr16-2325957417752260","volume-title":"13th International Workshop on Clinical Pharmacology of HIV Therapy","author":"Ramanathan S"},{"key":"bibr17-2325957417752260","volume-title":"16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy","author":"Ricard F"},{"key":"bibr18-2325957417752260","volume-title":"AIDS","author":"Diaz A","year":"2016"},{"issue":"3","key":"bibr19-2325957417752260","first-page":"816","volume":"72","author":"Gutierrez-Valencia A","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"bibr20-2325957417752260","doi-asserted-by":"publisher","DOI":"10.2165\/11584570-000000000-00000"},{"key":"bibr21-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku131"},{"key":"bibr22-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001193"},{"key":"bibr23-2325957417752260","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000103"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2325957417752260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2325957417752260","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2325957417752260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:49:13Z","timestamp":1777502953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2325957417752260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":23,"alternative-id":["10.1177\/2325957417752260"],"URL":"https:\/\/doi.org\/10.1177\/2325957417752260","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"2325957417752260"}}